Publisher Correction: Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis
Akihiro Matsukawa, Takafumi Yanagisawa, Mehdi Kardoust Parizi, Ekaterina Laukhtina, Jakob Klemm, Tamás Fazekas, Keiichiro Mori, Shoji Kimura, Alberto Briganti, Guillaume Ploussard, Pierre I. Karakiewicz, Jun Miki, Takahiro Kimura, Pawel Rajwa, Shahrokh F. Shariat
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProstate Cancer Treatment and Research · Chemotherapy-induced cardiotoxicity and mitigation · Cancer, Lipids, and Metabolism
Correction to: Prostate Cancer and Prostatic Diseases 10.1038/s41391-024-00886-0, published online 5 September 2024
In Table 3 of this article, the data in column 1–7 were mistakenly listed. Please see the corrected table below.
Table 3 Summary of NMA on cardiovascular events with ARSIs.Cardiac disorderHeart failureIHDAFHypertensionAny gradeGrade ≥3Any gradeGrade ≥3Any gradeGrade ≥3Any gradeGrade ≥3Any gradeGrade ≥3Data summary of included studies5 studie5 comparisons5786 patients7 studie7 comparisons6546 patients10 studies10 comparisons11,424 patients8 studies8 comparisons9157 patients6 studies6 comparisons7215 patients5 studies5 comparisons5820 patients11 studies11 comparisons9765 patients9 studies9 comparisons7,381 patients23 studies23 comparisons17,819 patients20 studies20 comparisons16,507 patientsSOCRR (95% CI)Ref.Ref.Ref.Ref.Ref.Ref.Ref.Ref.Ref.Ref.SUCRA value91%90%80%85%99%86%85%88%76%75%AbiRR (95% CI)1.48 (1.05–2.08)2.40 (1.42–4.06)1.77 (0.52–6.02)2.93 (0.51–16.86)NANA1.51 (0.96–2.38)2.07 (0.85–5.08)1.70 (1.32–2.19)2.19 (1.77–2.70)SUCRA value13%2%37%37%27%37%26%19%ApaRR (95% CI)NANA1.33 (0.42–4.17)1.92 (0.26–14.46)2.32 (0.97–5.54)2.08 (0.46–9.41)1.31 (0.63–2.71)1.55 (0.45–5.26)0.88 (0.53–1.46)0.63 (0.31–1.29)SUCRA value54%53%25%32%47%59%85%96%DarRR (95% CI)NANA2.09 (0.77–5.66)4.65 (0.25–88.20)NANANANA1.19 (0.57–2.49)1.47 (0.77–2.82)SUCRA value27%30%57%49%EnzRR (95% CI)1.24 (0.80–1.92)1.25 (0.73–2.13)1.40 (0.62–3.16)2.32 (0.74–7.28)2.38 (1.32–4.30)2.02 (0.62–6.63)1.37 (0.74–2.53)3.17 (1.05–9.58)2.08 (1.61–2.70)2.30 (1.82–2.92)SUCRA value46%58%53%44%26%31%41%15%5%12%RankingSOC>Enz>AbiSOC>Enz>AbiSOC>Apa>Enz>Abi>DarSOC>Apa>Enz>Abi>DarSOC>Enz>ApaSOC>Apa>EnzSOC>Apa>Enz>AbiSOC>Apa>Abi>EnzApa>SOC>Dar>Abi>EnzApa>SOC>Dar>Abi>EnzCochran’s Q testp = 0.03p = 0.2p = 0.9p = 0.9p = 0.01p < 0.01p = 0.4p > 0.9p < 0.001p = 0.5NMA network meta-analysis, RR risk ratio, CI Confidence Interval, IHD ischemic heart disease, AF atrial fibrillation, Ref reference, NA not available, SOC standard of care, Abi abiraterone, Enz enzalutamide, Apa apalutamide, Dar darolutamide.